Get the Stockscreener App
2.03
0.00%
0.00
After Hours:
2.04
0.01
+0.49%
C 4 Therapeutics Inc stock is traded at $2.03, with a volume of 852.77K.
It is up +0.00% in the last 24 hours and down -23.97% over the past month.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
See More
Previous Close:
$2.03
Open:
$2.05
24h Volume:
852.77K
Relative Volume:
0.47
Market Cap:
$196.74M
Revenue:
$20.76M
Net Income/Loss:
$-132.49M
P/E Ratio:
-0.7603
EPS:
-2.67
Net Cash Flow:
$-108.55M
1W Performance:
+3.57%
1M Performance:
-23.97%
6M Performance:
+37.16%
1Y Performance:
-50.37%
1-Day Range:
$2.015
$2.08
1-Week Range:
$1.87
$2.185
52-Week Range:
$1.085
$4.22
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Name
C 4 Therapeutics Inc
Sector
Industry
Phone
(617) 231-0700
Address
490 ARSENAL WAY, WATERTOWN
Compare CCCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.03 | 196.74M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Initiated | TD Cowen | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-15-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Dec-19-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Equal-Weight |
| Jan-29-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-13-23 | Upgrade | Stifel | Hold → Buy |
| Feb-24-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-24-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Apr-28-22 | Initiated | Credit Suisse | Underperform |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-10-22 | Initiated | JP Morgan | Overweight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Nov-23-21 | Initiated | BofA Securities | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-27-20 | Initiated | BMO Capital Markets | Outperform |
| Oct-27-20 | Initiated | Jefferies | Buy |
View All
C 4 Therapeutics Inc Stock (CCCC) Latest News
Brookline Capital Management Estimates C4 Therapeutics FY2030 Earnings - MarketBeat
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Fate Therapeutics reports new employee inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
Intellia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 31, 2025 - BioSpace
Sarepta Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Is C4 Therapeutics (CCCC) one of the best biotech penny stocks to buy according to analysts? - MSN
Is C4 Therapeutics (CCCC) One of the Best Biotech Penny Stocks to Buy According to Analysts? - Insider Monkey
Abeona Therapeutics® announces new employee inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Significant Growth in Short Interest - MarketBeat
With 43% stake, C4 Therapeutics, Inc. (NASDAQ:CCCC) seems to have captured institutional investors' interest - Yahoo Finance
C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Can C4 Therapeutics Inc. stock resist sector downturnsMarket Sentiment Report & Analysts Are Raving About These Shares - bollywoodhelpline.com
Is C4 Therapeutics Inc. stock in correction or buying zoneWeekly Profit Recap & Fast Moving Trade Plans - bolumsonucanavari.com
How C4 Therapeutics Inc. stock performs in weak economyWall Street Watch & Fast Exit and Entry Strategy Plans - Улправда
Energy Moves: How C4 Therapeutics Inc stock compares to growth peersWeekly Profit Analysis & Real-Time Stock Entry Alerts - moha.gov.vn
Can C4 Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Big Picture & Real-Time Buy Zone Alerts - Улправда
EV Market: Will C4 Therapeutics Inc. stock remain a Wall Street favoriteWeekly Investment Summary & Weekly Stock Breakout Alerts - Улправда
Exit Recap: Why C4 Therapeutics Inc. stock remains a top recommendationJuly 2025 Pullbacks & Real-Time Buy Zone Alerts - Улправда
Will C4 Therapeutics Inc. stock attract more institutional investors2025 Sector Review & Technical Pattern Based Signals - DonanımHaber
Layoff Watch: How C4 Therapeutics Inc. stock performs in weak economy2025 Trading Volume Trends & Safe Capital Investment Plans - Улправда
Will C4 Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Market Mood & Risk Controlled Stock Alerts - Улправда
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
How C4 Therapeutics Inc. stock performs during Fed tightening cycles2025 Risk Factors & Expert Approved Momentum Trade Ideas - Улправда
Why C4 Therapeutics Inc. stock remains a top recommendationDip Buying & Weekly High Return Stock Forecasts - Улправда
Barclays Maintains C4 Therapeutics (CCCC) Overweight Recommendation - Nasdaq
Barclays Lowers Price Target for C4 Therapeutics (CCCC) Despite Maintaining Overweight Rating | CCCC Stock News - GuruFocus
C4 Therapeutics Target of Unusually High Options Trading (NASDAQ:CCCC) - MarketBeat
Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price - simplywall.st
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 11, 2025 - BioSpace
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Travere Therapeutics (NASDAQ: TVTX) issues 20,300 new-hire RSUs vesting over four years - Stock Titan
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
What analysts say about C4 Therapeutics Inc stockEx-Dividend Date Alerts & Budget Friendly Trading Alerts - earlytimes.in
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
C 4 Therapeutics Inc Stock (CCCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
C 4 Therapeutics Inc Stock (CCCC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Boyle Scott N | Chief Business Officer |
Feb 14 '25 |
Sale |
3.15 |
490 |
1,544 |
110,842 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):